Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

BIOCRYST PHARMACEUTICALS, INC. (BCRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2013 | 07:45pm CEST

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:

http://www.monstertradingalerts.com/market-scan/?symbol=BCRX


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:

http://www.monstertradingalerts.com/market-scan/?symbol=GST

ABOUT US:

MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOCRYST PHARMACEUTICALS,
06/20BIOCRYST PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
AQ
06/20GREAT POINT PARTNERS, LLC : Remains Opposed To The BioCryst Pharmaceutical Propo..
PR
06/15BIOCRYST PHARMACEUTICALS : and Idera Pharmaceuticals to Present at the JMP Secur..
AQ
06/14BIOCRYST PHARMACEUTICALS : and Idera Pharmaceuticals to Present at the JMP Secur..
AQ
06/13BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Secu..
GL
06/05BIOCRYST PHARMACEUTICALS : Issues Letter to Stockholders Reiterating Upside Pote..
BU
05/31BIOCRYST PHARMACEUTICALS : Announces Presentation of Additional Analyses of the ..
AQ
05/30BIOCRYST PHARMACEUTICALS : Announces Presentation of Additional Analyses of the ..
AQ
05/29BIOCRYST PHARMACEUTICALS : Announces Presentation of Additional Analyses of the ..
AQ
05/28BIOCRYST PHARMACEUTICALS : and Idera Pharmaceuticals to Present at the Jefferies..
AQ
More news
News from SeekingAlpha
06/19INSTITUTIONAL TOP IDEAS : Great Point Partners 
05/10INSTITUTIONAL TOP IDEAS SERIES : Ra Capital Management 
05/08BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q1 2018 Results - Earn.. 
05/08BioCryst Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides 
05/08BioCryst Pharmaceuticals misses by $0.07, misses on revenue 
Financials ($)
Sales 2018 17,5 M
EBIT 2018 -85,8 M
Net income 2018 -94,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 31,5x
Capi. / Sales 2019 27,8x
Capitalization 552 M
Chart BIOCRYST PHARMACEUTICALS,
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Technical analysis trends BIOCRYST PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,83 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Jon P. Stonehouse President, Chief Executive Officer & Director
Robert Alexander Ingram Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab CFO, Treasurer, Principal Accounting Officer & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOCRYST PHARMACEUTICALS, INC.21.59%552
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196